NEW YORK, June 26, 2019 /PRNewswire/ -- CBM BioPharma Inc.
("CBM") today announced that the United States Patent &
Trademark Office (USPTO) has issued a Notice of Allowance and Issue
Fee Due in CBM's patent application related to the treatment of
pancreatic cancer.
CBM has received from the USPTO a Notice of Allowance for patent
application 15/115,393. This application is licensed from the
University of Texas by CBM. Once
the patent issue fee is paid, the new patent will protect one of
CBM's lead drug candidates, Gem-DHA, a novel gemcitabine derivative
intended for the treatment of pancreatic cancer. Preliminary
data indicates that Gem-DHA is more effective than gemcitabine in
mice pancreatic cancer models. This asset is to be sold to
Spherix Inc. (NASDAQ: SPEX) as part of the previously announced
Asset Purchase Agreement between CBM and Spherix. The
transaction is subject to shareholder approval by Spherix
shareholders and other customary closing conditions.
Anthony Hayes, Spherix CEO,
stated, "I am very excited by the potential of this drug and
especially by the data showing that Gem-DHA works better in
reducing the growth of pancreatic tumors than the first-line
chemotherapy drug gemcitabine. The data indicates that
Gem-DHA preferentially concentrates itself in the pancreas relative
to other organs, suggesting it may be a promising candidate for
further trials in pancreatic cancer. We are constantly
working to return value to our shareholders and this news is
another data point that establishes the value of the CBM
assets."
About CBM
CBM is a private biotechnology company with a drug portfolio
that focuses on the treatment of three cancers, acute myeloid
leukemia (AML), acute lymphoblastic leukemia (ALL) and pancreatic
cancer. CBM's AML drug is a next generation targeted therapeutic
designed to overcome multiple resistance mechanisms observed with
the current standard of care.
Support for PR Statements:
--Gem-DHA is a novel gemcitabine derivative intended for the
treatment of pancreatic cancer.
"The disclosed
compounds have a nucleobase moiety and an omega-3 polyunsaturated
fatty acid moiety, including pharmaceutically acceptable salt or
prodrug thereof. Methods of using these compounds for the
treatment of cancers such as pancreatic cancer are also disclosed."
(App. 15/115,393 at Abstract)
--Preliminary data indicate that Gem-DHA is more effective
than gemcitabine in mice pancreatic cancer models.
"The
results showed that Gem-DHA was more effective than the molar
equivalent dose of gemcitabine HCl in inhibiting the growth of
Panc-1-Luc tumors, but gemcitabine HCl at the dosing regimen used
did not significantly inhibit the growth of the Panc-1-Luc tumors
(FIG. 10A-C). In fact, by the end of the study, the average weight
of tumors in mice that were treated with gemcitabine HCl was not
significantly different from that in mice that were left untreated
(FIG. 10B)." (App. 15/115,393 at
Example 4)
--Gem-DHA works better in reducing the growth of pancreatic
tumors than the first-line chemotherapy drug
gemcitabine.
Repeating: "The results showed that Gem-DHA was more effective
than the molar equivalent dose of gemcitabine HCl in inhibiting the
growth of Panc-1-Luc tumors, but gemcitabine HCl at the dosing
regimen used did not significantly inhibit the growth of the
Panc-1-Luc tumors (FIG. 10A-C). In fact, by the end of the study,
the average weight of tumors in mice that were treated with
gemcitabine HCl was not significantly different from that in mice
that were left untreated (FIG. 10B)."
(App. 15/115,393 at Example 4)
--Gem-DHA preferentially concentrates itself in the pancreas
relative to other organs.
"Similar to what was observed in
tumor-bearing C.sub.57BL/6 mice (FIG. 16C), in healthy BALB/c mice,
the highest percent of the injected Gem-DHA was detected in mouse
pancreas (among the organs tested, FIG. 16D). Therefore, it
appeared that Gem-DHA preferred to distribute in pancreatic
tissues." (App. 15/115,393 at Example 5)
Contact:
Investor Relations
hbehrmann@cbmbiopharmainc.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/united-states-patent--trademark-office-allows-patent-claims-for-cbm-biopharma-incs-patent-application-for-pancreatic-cancer-treatment-300875038.html
SOURCE CBM BioPharma, Inc.